Vaccine Cost Research Articles

Optimising rabies vaccination of dogs in India.

Dog vaccination is the key to controlling rabies in human populations. However, in countries like India, with large free-roaming dog populations, vaccination strategies that rely only on parenteral vaccines are unlikely to be either feasible or successful. Oral rabies vaccines could be used to reach these dogs. We use cost estimates for an Indian city and linear optimisation to find the most cost-effective vaccination strategies. We show that an oral bait handout method for dogs that are never confined can reduce the per dog costs of vaccination and increase vaccine coverage. This finding holds even when baits cost up to 10x the price of parenteral vaccines, if there is a large dog population or proportion of dogs that are never confined. We suggest that oral rabies vaccine baits will be part of the most cost-effective strategies to eliminate human deaths from dog-mediated rabies by 2030.

COVID-19 and Malaria Vaccine Advanced Market Commitments: Opportunities to Incentivize Investment in Africa’s Vaccine Manufacturing Industry

Introduction Using push dynamics to drive the purchase of commodities with forecasted demand, the advanced market commitment (AMC) model has been applied to the development of vaccines catering to low-income countries in Africa and the globe. This model is currently the driving force behind both the delivery of COVID-19 vaccines to countries unable to afford open market prices and the roll out of the RTS,S/AS01 (Mosquirix) malaria vaccine in the WHO Africa region. Methods This literature review instills a comprehensive understanding of the costs associated with vaccine manufacturing development in the Africa region and draws particular focus to the prices paid by African national governments for the recently rolled out COVID-19 vaccines through the COMAX AMC as well as the estimated costs (based on birth cohort data and DPT vaccination coverage data) of the recently WHO recommended malaria vaccine program. Results Ethiopia, a GAVI supported country, is projected to pay between 4.2 and 9.9 million USD annually to vaccinate its target population with RTS,S/AS01b. GAVI ineligible countries such as South Africa and Egypt are projected to spend approximately 15.5 million and 43.3 million USD respectively. Of the GAVI ineligible and self financing countries, those with COVID-19 vaccine manufacturing capacity such as South Africa are able to access vaccine costs at 10 USD/dose compared to the 37 USD/dose spent by the 8 countries without manufacturing capacity. Results Investment in existing vaccine manufacturing companies in Eastern and Western Africa has projected growth with CAGR as high as 37% within 10 years. By purchasing and procuring vaccines from local regional manufacturing hubs, a number of donor un-supported self-financing countries in Africa have the potential to save up to 10 USD per vaccine dose.

Sustainable Development Goal Halftime Project: Benefit-Cost Analysis Using Methods from the Decade of Vaccine Economics Model

AbstractIn 2023, the world will be at “halftime” with respect to the sustainable development goals (SDGs). This midline acts as an important milestone to review the progress of the SDGs and develop policies based on the most effective interventions. To estimate the remaining resources needed to achieve SDG targets for vaccines from 2023 to 2030 as well the resulting economic benefits, in this analysis, the incremental economic benefit-cost ratio (BCR) for immunization programs in 80 low- and middle-income countries targeted by the Global Vaccine Action Plan from 2023 to 2030 is calculated. Of these 80 countries, 27 are classified as low-income countries and 53 are classified as lower-middle-income countries (LMICs). The economic evaluation covers 9 vaccines employed against 10 antigens and delivered through both routine immunization programs and supplemental immunization activities. The vaccines covered in the analysis include pentavalent vaccine, human papillomavirus vaccine, Japanese encephalitis vaccine, measles vaccine, measles-rubella vaccine, meningococcal conjugate A vaccine, pneumococcal conjugate vaccine, rotavirus vaccine, and yellow fever vaccine, and correspond to the vaccines covered in the return-on-investment estimates presented in Sim et al., which covered 94 LMICs from 2011 to 2030. For these countries, we estimate program costs from the health system perspective, including vaccine costs such as costs to procure vaccines, which incorporate injection supplies and freight; and immunization delivery costs, which include nonvaccine commodity costs to deliver immunizations to target populations and incorporate labor, cold chain and storage, transportation, facilities, training, surveillance, and wastage. Economic benefits are calculated using a value of statistical life year (VSLY) approach applied to modeled cases, and deaths averted are converted into averted years of life lost using life expectancy data. BCRs are presented as the final output that compares incremental costs and benefits from the baseline of 2022 levels, assuming diminishing returns to scale. Overall, for this period, we estimate total costs of US$ 7,581,837,329.08 with VSLY benefits of US$ 762,172,371,553.54, resulting in a BCR of 100.53.

Assessing the cost-effectiveness of annual COVID-19 booster vaccination in South Korea using a transmission dynamic model.

We evaluated the cost-effectiveness of South Korea's planned annual coronavirus disease 2019 (COVID-19) booster campaign scheduled for October 2023. An age-structured mathematical model was used to analyze the public impacts and cost-effectiveness of vaccination across three vaccination strategies: uniform allocation and prioritizing those over 65 or those over 50 years old. We calculated the incremental cost per quality-adjusted life year (QALY) from both healthcare and societal perspectives. The maximum vaccine cost for cost-effectiveness was also identified. Our analysis highlights the cost-effectiveness of South Korea's annual COVID-19 vaccination program in mitigating health and economic impacts. The most cost-effective strategy is uniform vaccine allocation, offering the lowest incremental cost-effectiveness ratio (ICER) at US$ 25,787/QALY. However, with a relatively high attack rate, the strategy prioritizing individuals over 65 years emerges as more cost-effective, lowering the ICER to US$ 13,785/QALY. Prioritizing those over 50 was less cost-effective. All strategies were cost-saving from a societal perspective, with cost-effectiveness being more sensitive to vaccine price than to its effectiveness. Our results imply a potential strategy shift in current vaccination plan, with uniform vaccine distribution being more cost-effective than prioritizing older adults. Early estimation of viral transmissibility and vaccine effectiveness is crucial in determining the most cost-effective vaccine allocation approach.

Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai

Dubai Health Authority currently recommends sequential administration of 13-valent pneumococcal conjugate vaccine (PCV13) followed by (→) 23-valent pneumococcal polysaccharide vaccine (PPV23) to prevent pneumococcal disease among adults at elevated risk of illness. Despite recommendations, disease burden and associated costs remain substantial. A new 20-valent pneumococcal conjugate vaccine (PCV20) recently received regulatory approval in the United Arab Emirates and has the potential to further reduce burden of pneumococcal disease. To evaluate budget impact of use of novel PCV20 compared with current recommendations (ie, PCV13→PPV23) among expatriates in Dubai aged 50 to 99 years and those aged 19 to 49 years with risk factors. A deterministic model depicted 5-year risks and costs of invasive pneumococcal disease and all-cause nonbacteremic pneumonia. Each year of the modeling horizon, persons could be vaccinated with either PCV20 or PCV13→PPV23 or remain unvaccinated; persons vaccinated during the modeling horizon were not eligible for vaccination in subsequent years. Annual vaccine uptake was assumed to be 5% in base cases analyses; higher uptake was considered in scenario analyses. Costs were discounted at 3.5% annually and reported in US dollars. In base case, use of PCV20 alone would prevent an additional 13 cases of invasive pneumococcal disease, 31 cases of inpatient all-cause nonbacteremic pneumonia, 139 cases of outpatient all-cause nonbacteremic pneumonia, and 5 disease-related deaths compared with PCV13→PPV23. Medical care costs would be reduced by $354,000, and total vaccination costs would decrease by $4.4 million. PCV20 would therefore yield net budgetary impact of -$4.8 million, resulting in savings of $2.47 per-person per-year over 5 years. In scenarios with higher vaccine uptake, PCV20 prevented more cases and deaths and yielded greater budget savings (vs PCV13→PPV23). PCV20 would reduce burden and economic costs of pneumococcal disease among expatriates in Dubai compared with PCV13→PPV23 and would therefore be budget saving for private health insurers who cover the majority of this population.

Coupling an individual adaptive-decision model with a SIRV model of influenza vaccination reveals new insights for epidemic control.

Past seasonal influenza epidemics and vaccination experience may affect individuals' decisions on whether to be vaccinated or not, decisions that may be constantly reassessed in relation to recent influenza related experience. To understand the potentially complex interaction between experience and decisions and whether the vaccination rate is likely to reach a critical coverage level or not, we construct an adaptive-decision model. This model is then coupled with an influenza vaccination dynamics (SIRV) model to explore the interaction between individuals' decision-making and an influenza epidemic. Nonlinear least squares estimation is used to obtain the best-fit parameter values in the SIRV model based on data on new influenza-like illness (ILI) cases in Texas. Uncertainty and sensitivity analyses are then carried out to determine the impact of key parameters of the adaptive decision-making model on the ILI epidemic. The results showed that the necessary critical coverage rate of ILI vaccination could not be reached by voluntary vaccination. However, it could be reached in the fourth year if mass media reports improved individuals' memory of past vaccination experience. Individuals' memory of past vaccination experience, the proportion with histories of past vaccinations and the perceived cost of vaccination are important factors determining whether an ILI epidemic can be effectively controlled or not. Therefore, health authorities should guide people to improve their memory of past vaccination experience through media reports, publish timely data on annual vaccination proportions and adjust relevant measures to appropriately reduce vaccination perceived cost, in order to effectively control an ILI epidemic.

Trends in managing COVID-19 from an emerging infectious disease to a common respiratory infectious disease: What are the subsequent impacts on and new challenges for healthcare systems?

Targeting the 9 countries with the highest cumulative number of newly confirmed cases in the past year, we analyzed the case fatality ratio (CFR) among newly confirmed cases and the vaccination rate (two or more doses of vaccine per 100 people) in the United States of America (USA), India, France, Germany, Brazil, the Republic of Korea, Japan, Italy, and the United Kingdom (UK) for the period of 2020-2022. Data reveal a decrease in the CFR among newly confirmed cases since the beginning of 2022, when transmission of the Omicron variant predominates, and an increase in vaccination rates. The Republic of Korea had the lowest CFR among newly confirmed cases (0.093%) in 2022 and the highest vaccination rate (86.27%). Japan had the second highest vaccination rate (83.12%) and a decrease in the CFR among newly confirmed cases of 1.478% in 2020, 1.000% in 2021, and 0.148% in 2022; while the average estimated fatality ratio for seasonal influenza from 2015-2020 was 0.020%. Currently, most countries are now easing COVID-19-related restrictions and are exploring a shift in management of COVID-19 from an emerging infectious disease to a common respiratory infectious disease that can be treated as the equivalent of seasonal or regional influenza. However, compared to influenza, infection with the Omicron variant still has a higher fatality ratio, is more transmissible, and the size of future outbreaks cannot be accurately predicted due to the uncertainty of viral mutation. More importantly, as countries shift their response strategies to COVID-19, there is an urgent need at this time to clarify what the subsequent impacts on healthcare systems and new challenges will be, including the clinical response, the dissemination of scientific information, vaccination campaigns, the creation of future surveillance and response systems, the cost of treatments and vaccinations, and the flexible use of big data in healthcare systems.

Estimating national, regional and provincial cost-effectiveness of introducing childhood 13-valent pneumococcal conjugate vaccination in China: a modelling analysis

Although 13-valent pneumococcal conjugate vaccine (PCV13) is available in China's private market, it has yet to be introduced into the National Immunization Programme (NIP) and is therefore not available to large parts of the population. This study aimed to estimate the cost-effectiveness of including PCV13 in China's NIP at national and provincial levels. We adopted a decision-tree Markov model to estimate the cost-effectiveness of adding 3-dose PCV13 in the NIP compared to the status quo in the private market from a societal perspective. The model hypothesized a birth cohort for five years after vaccine introduction. Treatment costs and vaccine program costs were calculated from Chinese Center for Disease Control and Prevention (CDC) and national insurance databases. Disease burden data, incidence rate ratios, and other parameters were derived from published and grey literature. Cases and deaths averted, quality-adjusted life years (QALYs) gained, and incremental cost-effectiveness ratios (ICERs) were estimated at the provincial, regional, and national levels. One-way, scenario and probabilistic sensitivity analyses were conducted to explore model uncertainty. At the national level, introducing PCV13 in the NIP was predicted to prevent approximately 4807 pneumococcal deaths (66% reduction) and 1,057,650 pneumococcal cases (17% reduction) in the first five years of the 2019 birth cohort. Under the assumed base case price of US$ 25 per dose in the NIP, PCV13 in the NIP was cost-effective nationally with ICER of US$ 5.222 per QALY gained, and was cost-effective in 17 and cost-saving in 4 of the 31provinces compared to the status quo. One-way and scenario sensitivity analyses indicated robust results when varying all model parameters, and probabilistic sensitivity analysis showed a 98% probability of cost-effectiveness nationally. Our findings highlight the cost-effectiveness of introducing PCV13 in China's NIP. Provincial results supported subnational introduction of PCV13, and priority should be given to less socioeconomically developed provinces. Since vaccination cost is the most influential model parameter, efforts to improve PCV affordability after pooled procurement will benefit public health in a cost-effective manner. The Bill & Melinda Gates Foundation.

Preventing Hepatitis B Virus Infection Among U.S. Military Personnel: Potential Impact of a 2-Dose Versus 3-Dose Vaccine on Medical Readiness.

Hepatitis B, a major public health issue worldwide, has been associated with serious clinical outcomes. Military personnel are at particular risk for hepatitis B, such that hepatitis B vaccination is part of the accession process for new recruits. Although lost time costs and medical cost avoidance have been used by the U.S. Military to guide their decision-making protocols, this has not been applied to hepatitis B vaccination costs. Herein, a decision-analytic model is used to compare the effective vaccine protection rates and vaccine and operational costs of 2-dose versus 3-dose hepatitis B vaccine regimens in a population of recruits from the U.S. Marine Corps Recruit Depot, Parris Island. A decision-analytic model was developed to assess the expected levels of adherence, seroprotection, and vaccination and operational costs of a cohort of recruits vaccinated with either a 2-dose (HepB-CpG) vaccine for those eligible (scenario 1) or a 3-dose (HepB-Alum) vaccine (scenario 2). De-identified data from 23,004 recruits at the Marine Corps Recruit Depot, Parris Island, in 2018 and 2019 were used to provide real-world data on age distribution and vaccination status. Other inputs included published data on adherence for hepatitis B vaccines and seroprotection rates for HepB-CpG and HepB-Alum in relation to the number of doses received. Costs included direct medical costs of the hepatitis B vaccination and operational costs such as missed training time. After receipt of two vaccine doses, 92% of recruits in scenario 1 (HepB-CpG group) were expected to be protected against hepatitis B within 1 month of receiving the second dose, compared with 24% of recruits in scenario 2 (HepB-Alum group), leaving 76% of Marine recruits unprotected if using HepB-Alum during the intervening 5-month period between doses 2 and 3. Over the study period, HepB-CpG was estimated to provide cost savings of $744,509 (17.3% cost reduction) compared with HepB-Alum, with the cost of missed training time being the most influential driver of the cost difference between the two vaccination schedules. Findings from this model suggest that vaccination with the 2-dose HepB-CpG vaccine may provide earlier and higher protection against hepatitis B compared with the 3-dose vaccine (HepB-Alum). A 2-dose vaccination strategy incorporated as part of individual medical readiness has the potential to not only increase protection but also confer economic savings among military recruits at risk for hepatitis B infection.

Green Closed-Loop Supply Chain Network Design During the Coronavirus (COVID-19) Pandemic: a Case Study in the Iranian Automotive Industry.

This paper presents a new mathematical model of the green closed-loop supply chain network (GCLSCN) during the COVID-19 pandemic. The suggested model can explain the trade-offs between environmental (minimizing CO2 emissions) and economic (minimizing total costs) aspects during the COVID-19 outbreak. Considering the guidelines for hygiene during the outbreak helps us design a new sustainable hygiene supply chain (SC). This model is sensitive to the cost structure. The cost includes two parts: the normal cost without considering the coronavirus pandemic and the cost with considering coronavirus. The economic novelty aspect of this paper is the hygiene costs. It includes disinfection and sanitizer costs, personal protective equipment (PPE) costs, COVID-19 tests, education, medicines, vaccines, and vaccination costs. This paper presents a multi-objective mixed-integer programming (MOMIP) problem for designing a GCLSCN during the pandemic. The optimization procedure uses the scalarization approach, namely the weighted sum method (WSM). The computational optimization process is conducted through Lingo software. Due to the recency of the COVID-19 pandemic, there are still many research gaps. Our contributions to this research are as follows: (i) designed a model of the green supply chain (GSC) and showed the better trade-offs between economic and environmental aspects during the COVID-19 pandemic and lockdowns, (ii) designed the hygiene supply chain, (iii) proposed the new indicators of economic aspects during the COVID-19 outbreak, and (iv) have found the positive (reducing CO2 emissions) and negative (increase in costs) impacts of COVID-19 and lockdowns. Therefore, this study designed a new hygiene model to fill this gap for the COVID-19 condition disaster. The findings of the proposed network illustrate the SC has become greener during the COVID-19 pandemic. The total cost of the network was increased during the COVID-19 pandemic, but the lockdowns had direct positive effects on emissions and air quality.

1370. The Impact of Increased Recombinant Zoster Vaccine Use on the Burden of Herpes Zoster Among Adults Aged 50 to 59 Years

Abstract Background Recombinant zoster vaccine (RZV) was approved by the Food and Drug Administration for prevention of herpes zoster (HZ) in adults aged ≥50 years in 2017 and recommended for this population by the Advisory Committee on Immunization Practices (ACIP) in 2018. Since the ACIP recommendation, vaccination rates have been increasing but are suboptimal for adults aged 50-59 years compared to adults aged ≥50 years overall. The objective of this study was to model the change in outcomes associated with improved vaccination rates in this population. Methods A multicohort Markov model was used to compare a scenario using the real-world vaccination rate for adults in the US aged 50-59 years in 2020 to a scenario assuming a higher vaccination rate based on that of adults aged 60-64 years in 2020. Outcomes, based on a lifetime horizon, included HZ cases and complications averted, quality-adjusted life-years (QALY), and costs. Model inputs, including age-specific HZ epidemiology, RZV efficacy, real-world RZV series completion, utilities, and costs (direct and indirect), were based on published literature and US sources. The size of the population aged 50-59 years was based on 2020 US census estimates. Schematic overview of Markov model structure HZ: herpes zoster; PHN: postherpetic neuralgia Results For the 43 million adults aged 50-59 years, increasing the percentage who received at least one dose of RZV from the current estimate of 7.3% in 2020 to 14.6%, assuming 80% series completion, could avoid an additional 504,468 HZ cases. An estimated additional 42,077 post-herpetic neuralgia cases and an additional 56,247 other complication cases of HZ could be avoided. Based on the estimated cases and complications avoided, an additional 5,230 discounted QALYs would be gained. Direct costs could be reduced by an additional $638 million (M) and indirect costs by $493M. With incremental vaccination costs of approximately $1,032M, from a societal perspective, cost savings of $99M would be realized. Conclusion Increasing RZV vaccination among adults aged 50-59 years could reduce the burden associated with HZ cases, complications, and result in fewer QALY losses. From a societal perspective, cost savings could be achieved in this population in addition to improved clinical outcomes. These findings demonstrate the potential value of increasing RZV vaccination for adults in the US aged 50-59 years. Disclosures David Singer, PharmD, MS, The GSK group of companies: Employed|The GSK group of companies: Stocks/Bonds Ahmed Salem, MSc, The GSK group of companies: Employed Nikita Stempniewicz, MSc, The GSK group of companies: Employed Siyu Ma, PhD, MBBS, The GSK group of companies: Grant/Research Support Sara Poston, PharmD, The GSK group of companies: Employed|The GSK group of companies: Stocks/Bonds Desmond Curran, PhD, The GSK group of companies: Employed|The GSK group of companies: Stocks/Bonds.

578. Cost-effectiveness of Infant Vaccination with PCV15 Compared to PCV13 in the United States

Abstract Background Streptococcus pneumoniae is a major cause of mortality and morbidity in young children. The 13-valent pneumococcal conjugate vaccine (PCV13) has been in routine use in children in the United States (US) since 2010. An investigational 15-valent vaccine (PCV15) that protects against two additional serotypes is currently under review by the FDA. This study aimed to evaluate the clinical and economic impact of routine infant vaccination with PCV15 compared with PCV13 from a US societal perspective. Methods A Markov decision-analytic model was developed to estimate the impact of PCV15 vs. PCV13 on pneumococcal disease incidence, post meningitis sequalae, and deaths. The model followed the entire US population over a 100-year time horizon, taking herd immunity effects into account. Each vaccination program comprised 3 primary doses and one booster for the new birth cohorts. Model inputs were obtained from the published literature, online databases, and unpublished data. PCV15 effectiveness was extrapolated from observed PCV13 data and PCV7 clinical trials. Costs (in 2021 USD) and quality-adjusted life years (QALYs) were discounted at 3% per year. Because the price for PCV15 in the pediatric indication is currently unknown, an analysis was conducted to determine the threshold price, which was defined as the maximum price for PCV15 to remain cost-saving. A series of sensitivity analyses were performed to test the robustness of model results. Results The base case results projected that PCV15 prevented 185,711 more invasive pneumococcal disease cases, 987,727 all-cause pneumonia cases and 11,151,473 pneumococcal acute otitis media and tube-replacement cases compared with PCV13. This resulted in an expected gain of 96,056 QALYs and total reduction of $7 billion in direct medical costs (excluding vaccine costs), and $4 billion in direct non-medical and indirect costs in the US population over the 100-year time horizon. The threshold price per dose for PCV15 was $28 higher than PCV13’s price. Sensitivity analyses showed the results to be robust over plausible values of key model inputs and assumptions. Conclusion Infant vaccination with PCV15 is projected to provide both clinical benefits and cost-savings compared with PCV13. Disclosures Min Huang, PhD, Merck & Co., Inc.: full-time employee Tianyan Hu, Ph.D., Merck & Co., Inc.: full time employee Jessica Weaver, PhD, MPH, Merck & Co., Inc.: Employee Kwame Owusu-Edusei, Ph.D., Merck & Co., Inc.: full time employee Elamin Elbasha, Ph.D., Merck & Co., Inc.: full time employee.

630. A Single-Center 10-Year Analysis of Immunizations in Heart Transplant Recipients

Abstract Background Vaccine-preventable diseases pose a risk towards heart transplant recipients on lifelong immunosuppression. Immunization rates are low (30-80%) in solid organ transplants. The aim of this study was to examine the vaccination rates in our hospital’s heart transplant recipients with a goal to expose deficiencies and formulate strategies to increase vaccination in this population. Methods This study is a single-center retrospective chart review of patients aged 18 or older who received a heart transplant between January 1, 2012 and March 31, 2022 at our institution in Temple, Texas. We documented vaccination status or seropositivity prior to or after transplant, as recommended by the American Society of Transplantation (AST) for influenza, hepatitis B, hepatitis A, measles, mumps, and rubella (MMR), 23-valent pneumococcal polysaccharide (PPSV23), 13-valent pneumococcal conjugate (PCV13), tetanus, diphtheria, and acellular pertussis (Tdap), varicella, zoster, and COVID-19 immunizations. We evaluated the association with an Infectious Disease (ID) consult. Odds ratios (OR) were calculated with 95% confidence intervals. Results 72 patients received a heart transplant within the 10-year period. Demographics are noted in table 1. Table 2 presents the immunization status as follows: 48.7% for flu vaccine, 55.5% for Hepatitis B, 47.1% for Hepatitis A, 36.1% for MMR, 67.5% for PPSV23, 67.5% for PCV13, 54.1% for Tdap, 83.3% for Varicella and 13.8% for Zoster, and 53.5% for COVID-19. From 2016, an ID consult was required pre-transplant; 45 patients (62.5%) had an ID consult before transplant. ID consult was associated with increased likelihood of receiving the MMR, PCV13, Tdap, and Zoster vaccines (table 3). Table 1Patient demographics Table 2 Immunization status in heart transplant recipients Table 3 Immunization status associated with ID consult Conclusion This study reveals the deficiency of vaccinations in our heart transplant patients, but an ID consult was associated with better immunization rates. To further increase compliance, we propose different interventions including close follow-up with ID, addressing vaccine costs, accessibility limitations, cultural hesitancy, and implementation of protocols. Disclosures All Authors: No reported disclosures.

Cost of oral cholera vaccine delivery in a mass immunization program for children in urban Bangladesh

Cholera poses a substantial health burden in the developing world due to both epidemic and endemic diseases. The World Health Organization recommends oral cholera vaccines for mass vaccination campaigns in addition to traditional prevention practices and treatments in resource-poor settings. In many developing countries like Bangladesh, the major challenge behind implementing mass vaccination campaigns concerns the affordability of the oral cholera vaccine (OCV). Vaccination of children with OCV is not only an impactful approach for controlling cholera at the population level and reducing childhood morbidity but is also considered more cost-effective than vaccinating all ages. The aim of the study was to estimate the cost of an OCV campaign for children from a societal perspective using empirical study. A total of 66,311 children aged 1 to 14 years old were fully vaccinated with two doses of the OCV Shanchol while 9,035 individuals received one dose of this vaccine. The estimated societal cost per individual for full vaccination was US$ 6.11, which includes the cost of vaccine delivery estimated at US$ 1.95. The cost per single dose was estimated at US$ 2.86. The total provider cost for full vaccination was estimated at US$ 6.01 and the recipient cost at US$ 0.10. Our estimation of OCV delivery costs for children was relatively higher than what was found in a similar mass OCV campaign for all age groups, indicating that there may be additional cost factors to consider in targeted vaccine campaigns. This analysis provides useful benchmarks for the possible costs related to delivery of OCV to children and future OCV cost-effectiveness models should factor in these possible cost disparities. Attempts to reduce the cost per dose are likely to have a greater impact on the cost of similar vaccination campaigns in many resource-poor settings.

Türkiye’de Üç Gün Hastalığı ve Ekonomik Boyutu

Bovine Ephemeral Fever (BEF) is a viral infection that causes a significant decrease in milk and meat production, infertility in cows and bulls, abortion and a significant economic loss due to its rapid spread in the herd. Partial budgeting method was used in the study to measure the economic impact of vaccine use and non-vaccination use. In line with preventive medicine, it has been determined that if animals are vaccinated regularly, there is an average of 8.10 (dolars) vaccination cost per animal, but the average treatment cost of an animal that has not been vaccinated during the epidemic is 20.2 (dolars). It was determined in the economic analysis that in addition to the treatment costs, the loss of milk for a dairy cow increased to approximately 85 (dolars), for a livestock to 148 (dolars) with the loss of condition, but the economic loss increased due to high morbidity. In this context, early diagnosis, detection and monitoring of spreading conditions are as extremely important as vaccination in the fight against BEF infection. It can be said that the economic loss will be minimized with the vaccination and preventive medicine practices to be made by rapid intervention to the disease with the early warning system created by the Ministry of Agriculture and Forestry for this purpose in Turkey.

Understanding hepatitis B vaccination willingness in the adult population in Indonesia: a survey among outpatient and healthcare workers in community health centers

AimThis study aimed to assess factors associated with the willingness to be vaccinated against hepatitis B among Indonesia’s adult population, considering cultural and geographic differences by analysing the two provinces of Aceh and Yogyakarta.Subject and methodsAn institution-based cross-sectional survey was conducted in 16 community health centres. A multivariable logistic regression model stratified by province was employed to assess variables associated with the willingness to receive hepatitis B vaccination.ResultsWe found that participants from Yogyakarta more often had a higher knowledge and risk perception of hepatitis B and were more often willing to get vaccinated than participants from Aceh. We also found that a high-risk perception of hepatitis B infection was associated with the willingness to be vaccinated against hepatitis B in participants from both Aceh and Yogyakarta. Furthermore, in Yogyakarta, a fair and high knowledge of hepatitis B infection and vaccination, being female, and having health insurance covering hepatitis B vaccination costs were associated with the willingness to be vaccinated. In Aceh, health care workers in high-risk units for hepatitis B had a higher willingness to be vaccinated than those who were not high-risk health care workers.ConclusionGiven the different factors associated with the willingness to be vaccinated against hepatitis B in Aceh and Yogyakarta, this study also highlights the need of a locally adjusted, culture-based approach to improve the hepatitis B vaccination programme.

Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications and Adverse Effects of JYNNEOS and ACAM2000 Monkeypox Vaccines.

Human monkeypox is an emerging viral zoonotic disease, that has caused highly distinctive, challenging and threatening problems worldwide. The US Food and Drug Administration (FDA) has given interim authorization for the JYNNEOS and ACAM2000 vaccines for the outbreak of monkeypox 2022. The present study aims to highlight the globally derived evidence about the biological and pharmacological features, indications, contraindications and adverse effects of JYNNEOS and ACAM2000 vaccines. Initially, 82 documents were selected and, finally, 14 fact sheets, documents and international organizations were included. The data were recorded from the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA) USA, ISI-Web of Science, PubMed, EMBASE and Scopus. The data revealed that the JYNNEOS vaccine has been recommended to children, adults, females during pregnancy and people of all age groups with a dose of 0.5 mL, and the complete vaccination cost per person is about USD 115. It provides immunogenicity, and the mean titer of neutralizing antibodies was 153.5. However, the ACAM2000 vaccine is contraindicated in infants and pregnant females, and recommended to people over 18 years of age and older, with a single dose of 0.0025 mL, and a cost of about USD 139. ACAM2000 provides immunogenicity, and the mean titer of neutralizing antibodies was 79.3. The JYNNEOS vaccine has mild adverse effects including pain, redness, swelling or itching at the site of the vaccine shot, fever, fatigue, headache, nausea and muscle pain. However, the ACAM2000 vaccine can cause pain, redness, edema, headache, fever, fatigue, muscle pain, body ache, nausea, vomiting, diarrhea, shortness of breath and increased risk of myopericarditis and cardiomyopathy. The evidence supports the view that both vaccines are beneficial, but the overall impact of JYNNEOS is better than that of ACAM2000.

Transcriptome analysis of differentially expressed circRNAs miRNAs and mRNAs during the challenge of coccidiosis.

Avian coccidiosis is a common enzootic disease caused by infection of Eimeria species parasites. It causes huge economic losses in the global poultry industry. Current control using anticoccidial drugs or vaccination is limited due to drug resistance and the relatively high cost of vaccines. Improving host genetic resistance to Eimeria species is considered an effective strategy for improved control of coccidiosis. Circular RNAs (circRNAs) have been found to function as biomarkers or diagnoses of various kinds of diseases. The molecular biological functions of circRNAs, miRNAs, and mRNAs related to Sasso chicken have not yet been described during Eimeria species challenge. In this study, RNA-seq was used to profile the expression pattern of circRNAs, miRNAs, and mRNAs in spleens from Eimeria tenella-infected and non-infected commercial dual-purpose Sasso T445 breed chickens. Results showed a total of 40 differentially expressed circRNAs (DEcircRNAs), 31 differentially expressed miRNAs (DEmiRNAs), and 820 differentially expressed genes (DEmRNAs) between infected and non-infected chickens. Regulatory networks were constructed between differentially expressed circRNAs, miRNAs, and mRNAs to offer insights into the interaction mechanisms between chickens and Eimeria spp. Functional validation of a significantly differentially expressed circRNA, circMGAT5, revealed that circMGAT5 could sponge miR-132c-5p to promote the expression of the miR-132c-5p target gene monocyte to macrophage differentiation-associated (MMD) during the infection of E. tenella sporozoites or LPS stimulation. Pathologically, knockdown of circMGAT5 significantly upregulated the expression of macrophage surface markers and the macrophage activation marker, F4/80 and MHC-II, which indicated that circMGAT5 might inhibit the activation of macrophage. miR-132c-5p markedly facilitated the expression of F4/80 and MHC-II while circMGAT5 could attenuate the increase of F4/80 and MHC-II induced by miR-132c-5p, indicating that circMGAT5 exhibited function through the circMGAT5-miR-132c-5p-MMD axis. Together, our results indicate that circRNAs exhibit their resistance or susceptive roles during E. tenella infection. Among these, circMGAT5 may inhibit the activation of macrophages through the circMGAT5-miR-132c-5p-MMD axis to participate in the immune response induced by Eimeria infection.

Societal Preferences for Meningococcal B Vaccination in Children: A Discrete Choice Experiment in Spain.

Immunization is the most effective strategy for the prevention of invasive meningococcal disease caused by Neisseriameningitidis serogroup B (MenB); however, parents need to weigh the risk-benefit and financial impact of immunizing their children against MenB in the absence of a national immunization program (NIP). This study aimed to explore societal preferences (of parents and pediatricians) regarding the attributes of a MenB vaccine in Spain. A discrete choice experiment (DCE) based on cross-sectional surveys was carried out to determine preferences. A literature review and scientific committee determined the six attributes related to the MenB vaccine included in the DCE: vaccination age, cost, duration, percentage of protection, adverse events probability, and expert/authority recommendation. Data were analyzed using a mixed logit model. Relative importance (RI) of attributes was calculated and compared between parents and pediatricians. A total of 278 parents [55.8% female, mean age 40.4 (standard deviation, SD 7.3) years] and 200 pediatricians [73.0% female, mean age 45.8 (SD 12.9) years] answered the DCE. For parents, the highest RI was attributed to vaccine cost, expert/authority recommendation, and percentage of protection (26.4%, 26.1%, and 22.9%, respectively), while for pediatricians the highest RI was assigned to percentage of protection, expert/authority recommendation, and vaccination age (27.2%, 23.7%, and 22.6%, respectively). Significant differences between parents and pediatricians were found in the RI assigned to all attributes (p < 0.001), except for vaccine recommendation. In the decision regarding MenB vaccination, cost was a driver in parental decision-making but had a low RI for pediatricians and, conversely, vaccination age was highly valued by pediatricians but was the attribute with least importance for parents. Despite these differences, expert/authority recommendation and percentage of protection were essential criteria for both groups. These results provide relevant information about MenB vaccination, highlighting the importance of considering societal preferences for NIP inclusion.

Cost-Utility Analysis of Universal Maternal Pertussis Immunisation in Thailand: A Comparison of Two Model Structures.

This study aimed to assess the cost-effectiveness of introducing universal maternal pertussis immunisation under the national vaccine programme in Thailand. We conducted a cost-utility analysis from a societal perspective to compare maternal vaccination with (1) TdaP vaccine, (2) Td vaccine and aP vaccine, and (3) Td vaccine only. We constructed two decision-tree models with Markov elements, each following a different clinical pathway, to allow us to examine structural uncertainty. Costs were converted to 2021 Thai Baht (THB) and a discount rate of 3% was applied to health and cost outcomes, with sensitivity analysis at 0% and 6%. Parameter uncertainty was investigated through deterministic and probabilistic sensitivity analysis, with expected value of perfect information analysis. Maternal pertussis vaccination would avert 27 cases and up to one death per year. The incremental cost-effectiveness ratio (ICER) for adding aP to the maternal immunisation schedule is 2,184,025 THB/QALY and the ICER for replacing maternal Td vaccination with TdaP is 3,198,101 THB/QALY. Maternal pertussis vaccination only becomes favourable in the probabilistic sensitivity analysis at cost-effectiveness thresholds above 6,000,000 THB/QALY, far above the Thai threshold of 160,000 THB/QALY. If incidence is less than 397 cases per 100,000, maternal pertussis vaccination will not be cost-effective in Thailand, within the plausible range for vaccine effectiveness and probability of hospitalisation. Budget impact is dominated by vaccination costs, which represent 12% and 18% of the 2021 national vaccine programme budget for introducing aP vaccine or for switching Td with TdaP vaccine, respectively. We have found that maternal pertussis immunisation is not cost-effective in Thailand. Although there may be substantial under-reporting of pertussis cases, comparison with hospital data suggests that most under-reported cases are not hospitalised and therefore have negligible impact on our results. However, considerations such as affordability and local manufacturing may also be important for national immunisation programme decision-making.